word sjs

8/11/2019 word sjs

1/8

oading the PowerPoint slide may take up to 30 seconds. If the slide opens in your browser,select File -> a!e "s to sa!e it.#opyright restrictions may apply. Please see our #onditions of $se.

%ownloading the PowerPoint slide may take up to 30 seconds. If the slide opens in yourbrowser, select File -> a!e "s to sa!e it.#opyright restrictions may apply. Please see our #onditions of $se.

Article Links Return to Article

http://pubs.ama-assn.org/misc/conditions.dtlhttp://pubs.ama-assn.org/misc/conditions.dtlhttp://archderm.ama-assn.org/cgi/content/full/144/1/25#DST70047T2http://archderm.ama-assn.org/cgi/content/full/144/1/25#DST70047F1http://pubs.ama-assn.org/misc/conditions.dtlhttp://archderm.ama-assn.org/cgi/content/full/144/1/25#DST70047T2http://pubs.ama-assn.org/misc/conditions.dtlhttp://archderm.ama-assn.org/cgi/content/full/144/1/25#DST70047F1

8/11/2019 word sjs

2/8

Figure 1.Flowchart of patients in the study. An asterisk indicates success

based on ability to decrease steroid dosages by 25% from baseline.

8/11/2019 word sjs

3/8

ownloading the PowerPoint slide may take up to 30 seconds. If the slide opens in yourbrowser, select File -> a!e "s to sa!e it.#opyright restrictions may apply. Please see our #onditions of $se.

Table 3. aseline !haracteristicsa

http://pubs.ama-assn.org/misc/conditions.dtlhttp://archderm.ama-assn.org/cgi/content/full/144/1/25#DST70047T3http://pubs.ama-assn.org/misc/conditions.dtlhttp://archderm.ama-assn.org/cgi/content/full/144/1/25#DST70047T3

8/11/2019 word sjs

4/8

Table ". #uccess and Failure of $apsone s &lacebo in Reducing #teroid

$osage to '.5 mg(d or )essa

ownloading the PowerPoint slide may take up to 30 seconds. If the slide opens in yourbrowser, select File -> a!e "s to sa!e it.#opyright restrictions may apply. Please see our #onditions of $se.

Figure 2.$osages of prednisone. A* For all patients treated with dapsone+ *

for all patients treated with placebo. An asterisk indicates the patientsswitched to the dapsone treatment group. The numbers in the key represent

number of patients.

http://pubs.ama-assn.org/misc/conditions.dtlhttp://archderm.ama-assn.org/cgi/content/full/144/1/25#DST70047F2http://pubs.ama-assn.org/misc/conditions.dtlhttp://archderm.ama-assn.org/cgi/content/full/144/1/25#DST70047F2

8/11/2019 word sjs

5/8

8/11/2019 word sjs

6/8

MulticenterRandomized, Double-blind, Placebo-Controlled, Clinicalrialo!Da"soneasa#lucocorticoid-$"aringAgentinMaintenance-P%asePem"%igus&ulgaris

8/11/2019 word sjs

7/8

,ictoria &. -erth* $+ $aid Fienson* $+ Amit /. &andya* $+ $iana !hen* $+. 0oyce Rico* $+ 0oerg Albrecht* $+ $aid 0acobus* $

Arch Dermatol.211+""4625732.

A'$RAC

(b)ecti*e To determine the efficacy o!da"soneasa glucocorticoid7s"aring

agentinmaintenance7"%ase"em"%igus*ulgaris4&,.

Design A randomi8ed* double7blind* placebo7controlledstudy with a crossoerarm for those who failed treatment.

$etting A 9# multicenteroutpatient study.

Patients A total o!: sub;ects enrolled among 5 centers*: randomi8ed to receie

da"soneand 1 to receie placebo. +nclusioncriteria were biopsy and directimmuno!luorescence7proen &,controlledwith glucocorticoids and(or cytoto

8/11/2019 word sjs

8/8

@BC!9RRB?T >##9BC&A$T >##9B#C T&>! !))B!T>?#C!BC#9>TC #9#!R>BC @B)&

!?$>T>?# (F 9#BC &R>,A!D &)>!DC !?TA!T 9#C #>TB A&

E 211 American edical Association. All Rights Resered.
http://archderm.ama-assn.org/http://archderm.ama-assn.org/current.dtlhttp://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#REF-DST70047-1http://archderm.ama-assn.org/current.dtlhttp://archderm.ama-assn.org/contents-by-date.0.dtlhttp://archderm.ama-assn.org/contents-by-date.0.dtlhttp://archderm.ama-assn.org/contents-by-date.0.dtlhttp://archderm.ama-assn.org/contents-by-date.0.dtlhttp://archderm.ama-assn.org/contents-by-date.0.dtlhttp://archderm.ama-assn.org/contents-by-date.0.dtlhttp://archderm.ama-assn.org/collections/http://cmejama-archives.ama-assn.org/http://cmejama-archives.ama-assn.org/http://manuscripts.archdermatol.com/http://manuscripts.archdermatol.com/http://manuscripts.archdermatol.com/http://archderm.ama-assn.org/misc/subscribe_landing.dtl?NAV_DERSUBhttp://archderm.ama-assn.org/misc/subscribe_landing.dtl?NAV_DERSUBhttp://archderm.ama-assn.org/help/?request=2009-03-05+04%3A50%3A02.281http://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#REF-DST70047-2http://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#REF-DST70047-2http://pubs.ama-assn.org/misc/conditions.dtlhttp://pubs.ama-assn.org/misc/conditions.dtlhttp://pubs.ama-assn.org/misc/conditions.dtlhttp://pubs.ama-assn.org/misc/conditions.dtlhttp://pubs.ama-assn.org/misc/conditions.dtlhttp://pubs.ama-assn.org/misc/privacy.dtlhttp://archderm.ama-assn.org/cgi/feedbackhttp://archderm.ama-assn.org/misc/sitemap.dtlhttp://pubs.ama-assn.org/misc/conditions.dtlhttp://pubs.ama-assn.org/misc/conditions.dtlhttp://pubs.ama-assn.org/misc/conditions.dtlhttp://pubs.ama-assn.org/misc/conditions.dtlhttp://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#REF-DST70047-1http://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#REF-DST70047-2http://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#REF-DST70047-11http://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#REF-DST70047-1http://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#REF-DST70047-12http://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#REF-DST70047-13http://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#REF-DST70047-1http://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#REF-DST70047-14http://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#REF-DST70047-20http://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#REF-DST70047-21http://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#REF-DST70047-22http://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#REF-DST70047-23http://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#tophttp://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#BDYhttp://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#SEC2http://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#SEC3http://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#SEC4http://archderm.ama-assn.org/cgi/content/full/144/1/25?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=multicenter+randomimed+double+blind+plasebo+controlled+clinical+trial+of+dapsone+as+aglucocorticoid+sparing+agent+in+maintenence+phase+pemphigus+vulgaris&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT#BIBLhttp://archderm.ama-assn.org/http://archderm.ama-assn.org/current.dtlhttp://archderm.ama-assn.org/contents-by-date.0.dtlhttp://archderm.ama-assn.org/collections/http://cmejama-archives.ama-assn.org/http://manuscripts.archdermatol.com/http://archderm.ama-assn.org/misc/subscribe_landing.dtl?NAV_DERSUBhttp://archderm.ama-assn.org/help/?request=2009-03-05+04%3A50%3A02.281http://pubs.ama-assn.org/misc/conditions.dtlhttp://pubs.ama-assn.org/misc/privacy.dtlhttp://archderm.ama-assn.org/cgi/feedbackhttp://archderm.ama-assn.org/misc/sitemap.dtlhttp://pubs.ama-assn.org/misc/conditions.dtl

Documents

word sjs